CL2021000881A1 - Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814 - Google Patents

Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814

Info

Publication number
CL2021000881A1
CL2021000881A1 CL2021000881A CL2021000881A CL2021000881A1 CL 2021000881 A1 CL2021000881 A1 CL 2021000881A1 CL 2021000881 A CL2021000881 A CL 2021000881A CL 2021000881 A CL2021000881 A CL 2021000881A CL 2021000881 A1 CL2021000881 A1 CL 2021000881A1
Authority
CL
Chile
Prior art keywords
methods
subject
skin
compositions
wounds
Prior art date
Application number
CL2021000881A
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021000881(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of CL2021000881A1 publication Critical patent/CL2021000881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente revelación tiene relación, en parte, con composiciones farmacéuticas que comprenden uno o más polinucleótidos adecuados para potenciar, aumentar, y/o suplementar los niveles de polipéptidos de cadena de Colágeno alfa-1 (VII) y/o polipéptido de lisil hidroxilasa 3 y/o polipéptido del citoesqueleto 17 de queratina tipo I en un sujeto. La presente revelación también tiene relación, en parte, a composiciones farmacéuticas y a métodos de uso para proporcionar alivio profiláctico, paliativo o terapéutico de una herida, trastorno o enfermedad de la piel en un sujeto, incluyendo un sujeto que tiene, o está en riesgo de desarrollar, uno o más síntomas de epidermólisis ampollosa.
CL2021000881A 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814 CL2021000881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
CL2021000881A1 true CL2021000881A1 (es) 2021-09-10

Family

ID=57822104

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018002814A CL2018002814A1 (es) 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2021000881A CL2021000881A1 (es) 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814
CL2023000743A CL2023000743A1 (es) 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018002814A CL2018002814A1 (es) 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000743A CL2023000743A1 (es) 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Country Status (21)

Country Link
US (7) US9877990B2 (es)
EP (2) EP3377637B1 (es)
JP (3) JP6970086B2 (es)
KR (1) KR20180128016A (es)
CN (1) CN109072255A (es)
AU (3) AU2016401692B2 (es)
CA (1) CA3017487A1 (es)
CL (3) CL2018002814A1 (es)
CY (1) CY1123024T1 (es)
DK (1) DK3377637T3 (es)
ES (1) ES2796488T3 (es)
HR (1) HRP20200853T1 (es)
HU (1) HUE049237T2 (es)
LT (1) LT3377637T (es)
MX (2) MX2018012135A (es)
PL (1) PL3377637T3 (es)
PT (1) PT3377637T (es)
RS (1) RS60410B1 (es)
SG (1) SG11201808314QA (es)
SI (1) SI3377637T1 (es)
WO (1) WO2017176336A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
US10864153B2 (en) * 2016-11-14 2020-12-15 The Regents Of The University Of Michigan Compositions and methods for blocking ultraviolet radiation
EP3568474A1 (en) 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) * 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
WO2020068862A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
EP3856914A1 (en) * 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
JPWO2020149395A1 (ja) * 2019-01-18 2021-11-25 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
AU2020219343A1 (en) 2019-02-08 2021-08-19 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
TWI818166B (zh) * 2019-03-27 2023-10-11 美商菲尼克斯組織修復公司 用於生產膠原蛋白7組合物之系統及方法
AU2020341451A1 (en) 2019-09-03 2022-03-24 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
WO2023064806A1 (en) 2021-10-12 2023-04-20 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
ATE388720T1 (de) * 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1083951A4 (en) * 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
CA2356937A1 (en) 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
CA2430341A1 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006050211A2 (en) * 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2006079014A2 (en) * 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
JP6480874B2 (ja) * 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Ｔａｌｅｎに基づく遺伝子修正
PL2968586T3 (pl) * 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
US10174341B2 (en) 2013-07-17 2019-01-08 University of Pittsburgh—of the Commonwealth System of Higher Education Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
KR20220100078A (ko) 2014-01-31 2022-07-14 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
CN113559246A (zh) * 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
WO2017106202A2 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
ES2924521T3 (es) * 2016-03-25 2022-10-07 Periphagen Inc Vectores del VHS para la administración de NT3, y tratamiento de la CIPN
DK3432912T3 (da) * 2016-03-25 2023-03-13 Periphagen Inc Hsv-vektorer med høj transduktion
PL3377637T3 (pl) 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
AU2019292580A1 (en) 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
KR20180128016A (ko) 2018-11-30
US20200101123A1 (en) 2020-04-02
US11865148B2 (en) 2024-01-09
CL2023000743A1 (es) 2023-09-29
SI3377637T1 (sl) 2020-08-31
JP2023118838A (ja) 2023-08-25
CY1123024T1 (el) 2021-10-29
AU2022204729A1 (en) 2022-07-21
RS60410B1 (sr) 2020-07-31
EP3377637A1 (en) 2018-09-26
AU2016401692A1 (en) 2018-09-27
LT3377637T (lt) 2020-07-10
US20170290866A1 (en) 2017-10-12
EP3377637B1 (en) 2020-03-18
HRP20200853T1 (hr) 2020-08-21
WO2017176336A1 (en) 2017-10-12
NZ746213A (en) 2021-08-27
US10441614B2 (en) 2019-10-15
US20230149486A1 (en) 2023-05-18
US20220273737A1 (en) 2022-09-01
ES2796488T3 (es) 2020-11-27
JP2019513689A (ja) 2019-05-30
PT3377637T (pt) 2020-06-17
US20190160122A1 (en) 2019-05-30
AU2016401692B2 (en) 2019-10-03
MX2022006072A (es) 2022-06-14
DK3377637T3 (da) 2020-05-18
SG11201808314QA (en) 2018-10-30
US9877990B2 (en) 2018-01-30
JP6970086B2 (ja) 2021-11-24
AU2019280069B2 (en) 2022-04-07
AU2019280069A1 (en) 2020-01-16
JP7480105B2 (ja) 2024-05-09
US10155016B2 (en) 2018-12-18
MX2018012135A (es) 2019-03-28
EP3712273A1 (en) 2020-09-23
HUE049237T2 (hu) 2020-09-28
US20230414686A1 (en) 2023-12-28
CL2018002814A1 (es) 2019-02-15
PL3377637T3 (pl) 2020-09-07
US11185564B2 (en) 2021-11-30
CA3017487A1 (en) 2017-10-12
JP2022023174A (ja) 2022-02-07
US20180169160A1 (en) 2018-06-21
CN109072255A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
CL2021000881A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
ECSP16094261A (es) Formulaciones y métodos de tratamiento con queratina
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
AR052057A1 (es) Composiciones orales que contienen extractos de rosmarinus y metodos ralacionados
EA201591413A1 (ru) Композиции и способы для лечения поверхностных ран
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
BR112019001142A2 (pt) vírus vaccinia recombinante e uso do mesmo
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
BR112015029926A2 (pt) combinação de agentes ativos para o tratamento de envelhecimento da pele
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2018013860A (es) Composiciones cosmeticas para reparacion cutanea.
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
DOP2023000223A (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112015024221A2 (pt) exopolissacarídeo, uso do exopolissacarídeio, e, composição cosmética ou dermofarmacêutica
BR112019006174A2 (pt) proteina terapêutica
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
WO2015069888A3 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
CL2021000660A1 (es) Compuestos quelantes de hierro para tratar condiciones estéticas de la piel
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
BR112017022390A2 (pt) composição farmacêutica